Exploratory Study Evaluating the Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris, Using a Split-Face Model

The aim of this proof of principle study is to evaluate efficacy and safety of the sequential application of two marketed products for the treatment of acne vulgaris, using the Split-Face model

开始日期2011-11-01

申办/合作机构

Leo Pharma, Inc.

100 项与维甲酸维E酯相关的临床结果

登录后查看更多信息

100 项与维甲酸维E酯相关的转化医学

登录后查看更多信息

100 项与维甲酸维E酯相关的专利（医药）

登录后查看更多信息

项与维甲酸维E酯相关的文献（医药）

2020-05-01·Lung Cancer2区 · 医学

Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)

2区 · 医学

Article

作者: Dudnik, Elizabeth ; Rotem, Ofer ; Moore, Assaf ; Shochat, Tzippy ; Sherman, Shira ; Zer, Alona

OBJECTIVESLittle is known regarding the ICPi efficacy in LCNEC. We explored the efficacy and safety of ICPi in LCNEC and assessed its impact on OS.MATERIALS AND METHODSThirty-seven consecutive patients with advanced LCNEC were selected from the Davidoff Cancer Center database. These were divided into groups A1 (patients treated with ICPi, n-23) and A2 (patients not treated with ICPi, n-14). Additionally, group A1* was introduced (patients treated with ICPi as a monotherapy, n-21). Another cohort of advanced non-LCNEC lung cancer patients treated with nivolumab at five Israeli cancer centers was chosen as a comparator (group B, n-270). ORR, PFS with ICPi in group A1* were assessed (RECIST 1.1), OS with ICPi was compared between groups A1* and B. OS since advanced disease diagnosis (OSDx) was compared between groups A1 and A2.RESULTSIn group A1*, ORR and median PFS with ICPi were 33 %, and 4.2 months (95 % CI, 2.4-8.1), respectively. With median follow-up since start of ICPi of 6.2 months [IQR 2.2-12.1] and 4.9 months [IQR 2.3-8.9] in groups A1* and B, respectively, 52 % and 64 % of patients died in groups A1* and B, respectively. Median OS with ICPi comprised 11.8 months (95 % CI, 3.7-NR) and 6.9 months (95 % CI, 5.5-8.1) in groups A1* and B, respectively (p-0.23). Median OSDx was 14.5 months (95 % CI, 10.1-38.9) and 10.3 months (95 % CI, 2.6-NR), in groups A1 and A2, respectively (p-0.54).CONCLUSIONIn advanced LCNEC, ICPi outcomes are comparable to the outcomes observed in advanced NSCLC. Future research is needed to clarify the impact of ICPi on OS, and to correlate its benefit with tumor mutational landscape.

2013-10-01·Journal of Dermatological Science2区 · 医学

Reagents inducing epidermal proliferation also induce pigmentation: Induction of keratinocyte proliferation as a novel strategy for the treatment of vitiligo

2区 · 医学

Letter

作者: Mayumi Komine ; Mamitaro Ohtsuki ; Chieh-Shan Wu ; Yayoi Tada ; Kanako Kikuchi ; Seiki Fujimoto ; Hanako Ohmatsu ; Hsin-Su Yu ; Kunihiko Tamaki

A review.This article hypothesis the reagents inducing epidermal keratinocytes proliferation also induce pigmentation for treatment of vitiligo.The reagents used for proliferation are tacrolimus, alprostadil, alfadex, bendazac, etretinate, trafermin, phenytoin, bucladesine sodium, tretinoin tocoferil.

2012-10-01·Pharmaceutical Research3区 · 医学

Powder Strength Distributions for Understanding De-agglomeration of Lactose Powders

3区 · 医学

Article

作者: Srinivas Ravindra Babu Behara ; David Alexander Vodden Morton ; Ian Clair Larson ; Jurgen Bernd Bulitta ; Peter James Stewart ; Shyamal Chandra Das

PURPOSEThe purpose was to calculate distributions of powder strength of a cohesive bed to explain the de-agglomeration of lactose.METHODSDe-agglomeration profiles of Lactohale 300(®) (L300) and micronized lactose (ML) were constructed by particle sizing aerosolised plumes dispersed at air flow rates of 30-180 l/min. The work of cohesion distribution was determined by inverse gas chromatography. The primary particle size and tapped density distributions were determined. Powder strength distributions were calculated by Monte Carlo simulations from distributions of particle size, work of cohesion and tapped density measurements.RESULTSThe powder strength distribution of L300 was broader than that of ML. Up to 85th percentile, powder strength of L300 was lower than ML which was consistent with the better de-agglomeration of L300 at low flow rates. However, ~15% of L300 particles had higher powder strength than ML which likely to cause lower de-agglomeration for L300 at high air flow rates.CONCLUSIONCohesive lactose powders formed matrices of non-homogenous powder strength. De-agglomeration of cohesive powders has been shown to be related to powder strength. This study provided new insights into powder de-agglomeration by a new approach for calculating powder strength distributions to better understand complex de-agglomeration behaviour.

100 项与维甲酸维E酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01516	-	D10AD01 L01XX14	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
压疮	日本	Sun Pharmaceutical Industries Ltd.	1992-10-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01461655 (CTgov)	临床2期	寻常痤疮	40	vehicle gel+marketed topical retinoid (Topical Retinoid - Placebo)	範鹽顧醖築顧淵簾憲憲(壓鑰繭襯觸構憲廠鏇憲) = 鏇膚廠淵願範夢夢繭齋繭鹽衊夢淵選膚淵窪壓 (膚網構構襯簾範製膚壓, 膚鹹齋鬱壓鹹積餘憲壓 ~ 鏇夢醖襯蓋鬱膚積願糧) 更多	-	2013-12-04
				marketed topical NSAID+marketed topical retinoid (Topical Retinoid-NSAID)	範鹽顧醖築顧淵簾憲憲(壓鑰繭襯觸構憲廠鏇憲) = 齋顧廠窪廠壓範觸襯衊繭鹽衊夢淵選膚淵窪壓 (膚網構構襯簾範製膚壓, 鏇獵觸鹽憲鹽衊觸積壓 ~ 窪鹽構蓋範餘醖蓋窪蓋) 更多